Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugemalimab in relapsed or refractory extranodal NK/T-cell lymphoma
CTR20180519Phase 2Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by CStone Pharmaceuticals. Started May 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on CTR20180519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180519.